By Scott Gottlieb (Original source The Cut)
Well, shoot.
“The FDA commissioner Scott Gottlieb announced his unexpected resignation on Tuesday, in a letter the FDA tweeted. The reasons are unclear, but it leaves a lot of people extremely disappointed, myself among them. (He’s been commuting to D.C. from Connecticut and says he misses his wife and young family.)
Since his appointment in May of 2017, Gottlieb has earned wide bipartisan support as a public-health advocate (also unexpected, given his previous ties to the pharmaceutical industry), due in large part to his efforts to curb the opioid epidemic, which he told CNN last year was the “biggest crisis” facing the FDA. “Gottlieb has been shockingly good so far,” Stanford public policy expert Keith Humphreys told Vox. (However, Harvard professor and FDA-scrutinizer Daniel Carpenter said the “jury is still out” on Gottlieb’s legacy, in an interview with STAT.)”
Click here to see more
Erika Ayers Badan: How to Keep Creativity Alive
Hi! Ever felt like you’re on a Disney ride through every big-company headache imaginable? Think lawyers, bankers, finance goons, stale conference rooms, staid conversations and…
Thought Leader: Erika Ayers Badan
Chris Miller: Trump’s Nvidia Chip Decision Lands Hard
In a new article, “Allowing China access to advanced semiconductors puts national security and U.S. AI industry at risk,”Chris Miller — author of Chip War…
Thought Leader: Chris Miller
Chris Miller: Nvidia’s H200 Chip Sales to China
In a move with major implications for national security and the race to dominate artificial intelligence, President Trump announced Monday that he will allow Nvidia…
Thought Leader: Chris Miller
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb
Scott Gottlieb: China’s edge over U.S. biotech
Thought Leader: Scott Gottlieb
